| 摘要 |
<p>The rise in intraocular pressure associated with the use of steroidal anti-inflammatory drugs is controlled by use of angiotensin converting enzyme inhibitors.</p><p>For the purposes of the invention, the preferred ACE inhibitor is 7-[N-(1(S)-carboxy-3-phenylpropyl)-(S)-alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid. </p> |
